You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

ZIMHI Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Zimhi patents expire, and when can generic versions of Zimhi launch?

Zimhi is a drug marketed by Zmi Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has ten patent family members in nine countries.

The generic ingredient in ZIMHI is naloxone hydrochloride. There are twelve drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zimhi

A generic version of ZIMHI was approved as naloxone hydrochloride by HOSPIRA on September 24th, 1986.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ZIMHI?
  • What are the global sales for ZIMHI?
  • What is Average Wholesale Price for ZIMHI?
Summary for ZIMHI
International Patents:10
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 57
Patent Applications: 1,704
Drug Prices: Drug price information for ZIMHI
What excipients (inactive ingredients) are in ZIMHI?ZIMHI excipients list
DailyMed Link:ZIMHI at DailyMed
Drug patent expirations by year for ZIMHI
Drug Prices for ZIMHI

See drug prices for ZIMHI

Pharmacology for ZIMHI
Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists

US Patents and Regulatory Information for ZIMHI

ZIMHI is protected by four US patents.

Patents protecting ZIMHI

Emergency devices
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF AN OPIOID ANTAGONIST COMPRISING AN EMERGENCY SYRINGE DEVICE


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF AN OPIOID ANTAGONIST COMPRISING AN EMERGENCY SYRINGE DEVICE INCLUDING A NEEDLE GUARD


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF AN OPIOID ANTAGONIST COMPRISING AN EMERGENCY SYRINGE DEVICE INCLUDING A WINDOW CONFIGURED TO ALLOW THE USER TO VIEW THE OPIOID ANTAGONIST IN THE SYRINGE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zmi Pharma ZIMHI naloxone hydrochloride SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 212854-001 Oct 15, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Zmi Pharma ZIMHI naloxone hydrochloride SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 212854-001 Oct 15, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ZIMHI

See the table below for patents covering ZIMHI around the world.

Country Patent Number Title Estimated Expiration
South Korea 20210013617 응급 장치 ⤷  Sign Up
China 112469458 紧急装置 (EMERGENCY DEVICES) ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2019227061 ⤷  Sign Up
Japan 2021524328 緊急デバイス ⤷  Sign Up
European Patent Office 3801699 DISPOSITIFS D'URGENCE (EMERGENCY DEVICES) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZIMHI

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1685839 92292 Luxembourg ⤷  Sign Up PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.